Search PubMed⌕ Search

Biomedical subjects

C Ronco

Publications and source records attributed to C Ronco.

At least 145 records · Page 8Linked to original sources
PubMed1999

Haemodialysis filters: what's new?

Haemodialysis techniques rely on efficient haemodialyzers that are utilized as solute and water exchangers. The haemodialyzer design has not changed significantly for many years. Only recently optimization of the blood compartment design, of the membrane structure and of the dialysate compartment geometry have been sought. This paper briefly reviews the most recent advances in the design and construction of haemodialyzers and points out the clinical impact of such innovations.

Equipment Design↗
PubMed1999

New perspectives in the treatment of acute renal failure.

The evolution of technology and biomaterials has permitted a parallel development of renal replacement therapies in the acute, critically ill patient. From the original description of continuous arterio-venous haemofiltration, new techniques such as continuous veno-venous haemofiltration, haemodiafiltration and high flux dialysis have been developed and clinically utilised. A parallel improvement in efficiency has been achieved with urea daily clearances as high as 50 litres or more. The use of special highly permeable dialysers has also permitted to increase the clearances of larger solutes thus leading to significant removals of chemical substances involved in the acute inflammation and sepsis. In this field, recent observations have suggested to use haemofiltration with high volumes of fluid exchange. The hardware and software of the newer continuous renal replacement therapies (CRRT) are certainly the key point in achieving these results and in safely performing such challenging techniques.

Acute Kidney Injury↗
PubMed1999

Changing acute renal failure treatment from intermittent hemodialysis to continuous hemofiltration: impact on azotemic control.

BACKGROUND: Continuous renal replacement therapy is increasingly used in the management of acute renal failure in critically ill patients. The advantages of continuous renal replacement therapy (CRRT) over intermittent hemodialysis (IHD), however, are not yet fully documented. In particular, it is unknown whether continuous veno-venous hemodiafiltration (CVVHDF) provides better control of azotemia than IHD. OBJECTIVES: To study the effect on azotemic control of changing acute renal failure treatment from IHD to CVVHDF. SETTINGS: Tertiary intensive care unit. PATIENTS: Forty seven consecutive critically ill patients with multiorgan failure and acute renal failure treated with IHD and 47 similar patients treated with CVVHDF. METHODS: Analysis of daily morning urea and creatinine concentrations over the period of renal replacement therapy in the ICU. Statistical comparison of data. RESULTS: The two groups of patients were comparable for mean age (55 years for IHD vs. 60 years for CVVHDF; NS) and number of failing organs prior to therapy (mean of 4.2 for IHD vs. 3.7 for CVVHDF; NS). Severity of illness at admission as assessed by APACHE II score, however, was greater for patients receiving CVVHDF (29.4 vs 25.7; p<0.003). CVVHDF was associated with a significantly lower plasma urea (p < 0.0001) and serum creatinine (p < 0.01) level at 24 hours of treatment despite similar levels at the start of therapy Throughout the duration of therapy, mean urea levels (35.0 mmol/L for IHD vs 23.4 mmol/L for CVVHDF) and mean serum creatinine levels (513 micromoles/L for IHD and 263 micromoles/L for CVVHDF) showed significantly (p <0.0001) better control of uremia with CRRT. CONCLUSIONS: Changing the form of renal replacement therapy from intermittent hemodialysis to continuous hemofiltration is associated with improved control of azotemia. The superior adequacy of small solute clearance achieved during CVVHDF provides additional support for its preferential use in the management of acute renal failure in the ICU.

Acute Kidney Injury↗
PubMed1999

Present and future options in continuous renal replacement therapies of sepsis and MOF.

Conventional continuous extracorporeal treatments such as hemofiltration and hemodiafiltration have not achieved significant reduction in cytokine plasma levels, in spite of their increasing popularity mainly related to the unnecessary fluid restriction thereby rendering adequate caloric intake possible (Actualités Nephrologiques, 1994). This is mainly due to reduced filtration, to saturability of the adsorption-related phenomena and to the absence of a convective mass transfer. New approaches have been more recently introduced. The concept of blood purification has been applied in some new innovative techniques that use non-selective or selective sorbents. We will focus on the criteria used by others and us to assess the efficiency in vitro and in animal models of sepsis of more recently introduced non-selective and selective devices. Among the innovative techniques, modalities aimed at the plasma treatment will receive emphasis. These modalities that are based on plasma filtration with the use of different sorbents. The preliminary results obtained from ongoing clinical trials will be presented. We will also expand on the technical, biological and clinical aspects that should be addressed in order to establish a new modality as innovative in the treatment of sepsis.

Hemofiltration↗
PubMed1999

Results from ethical international surveys on the management of the continuous renal replacement therapy.

OBJECTIVE: To examine the ethical approach of clinicians to the continuous renal replacement therapy (CRRT). DESIGN: Review of international surveys. RESULTS: Many surveys have been carried out in order to evaluate the clinical approach and management of the continuous renal replacement therapy (CRRT). Nothing has been proposed in order to evaluate it from a bioethical point of view, even if many surveys dealt with the problem of the ethically correct administration of vital supports. These data demonstrate that an ethically correct approach to the management of life-saving support can be sometimes difficult. Results of a recent study on the ethical approach of intensivists and nephrologists to CRRT will be shown and discussed. CONCLUSIONS: Several ethical questions in the management of CRRT and other vital support are still unsolved. Practical and psychological aspects of the curing process are sometimes stronger than bioethical principles.

Ethics, Medical↗
PubMed1999

Extracorporeal therapies: should we use plasma instead of blood?

The evolution of extracorporeal therapies has required the parallel evolution of devices designed to extract the blood from the patient and to move it in the extracorporeal circuit. Blood is a peculiar fluid in which viscosity may be strongly affected by the contingent operational conditions of the extracorporeal circuit. Because hematocrit is an important component of blood viscosity, and viscosity may definitely affect the performance of blood purification devices, major problems arise when high hematocrits are present in the patient. All these problems might be avoided if plasma could be used instead of whole blood. Plasma treatment is already performed in various therapies, but the treated plasma is obtained by separation from whole blood in the extracorporeal environment. In this paper we propose a new approach to perform different plasma treatments. Plasma is extracted directly from the patient thanks to a special catheter or plasma extraction device. Utilizing plasmafiltration technology to create a membrane that is placed on the tip of an intravascular catheter, plasma extraction may become easy to perform. The extracted plasma is then available for any type of treatment before being restituted to the patient via a second lumen in the same catheter.

Animals↗
PubMed1999

In vitro and in vivo evaluation of a new polysulfone membrane for hemodialysis. Reference methodology and clinical results. (Part 1: in vitro study).

Different high flux membranes have been recently developed. The present study is aimed at describing the technical features and the clinical performances of a new high flux polysulfone membrane (T-sulfone, Toray, Japan). The study has been carried out on two different dialyzers (surface area = 1.3 and 1.8 m2). The filters have been tested in vitro under definite experimental conditions. The hydraulic flow resistance, the pressure drop in the blood compartment and the hydraulic permeability have been determined in a wide range of in vitro experimental conditions. The in vitro sieving coefficients for various solutes have also been determined utilizing human blood. Hydraulic permeability was found in the range of 28.4 ml/h/mm Hg/m2 and sieving coefficients were between 0.96 and 1.0 for all low molecular weight solutes. The sieving coefficient for inulin was 0.95. The pressure drop in the filter at 300 ml/min of blood flow was 95 mm Hg for the 1.3 m2 and 57 mm Hg for the 1.8 m2. The filters are then designed to operate in the presence of high blood flows without excessive resistance in the blood compartment. The blood compartment analyzed by means of a special radiological sequence obtained with a helical scanner after dye injection confirmed the homogeneous distribution of the blood flow in several cross sections of the bundle. Adequate distribution of dialysate was confirmed with a similar method applied to the dialysate compartment. The new imaging techniques utilized were greatly helpful to determine adequacy of filter design and flows distribution.

Biocompatible Materials↗
PubMed1999

In vitro and in vivo evaluation of a new polysulfone membrane for hemodialysis. Reference methodology and clinical results. (Part. 2: in vivo study).

Different high flux membranes have been recently developed. The present study is aimed at describing the technical features and the clinical performances of a new high flux polysulfone membrane (T-sulfone, Toray, Japan). The study has been carried out on two different dialyzers (surface area = 1.3 and 1.8 m2). The filters have been tested in vivo during hemodialysis and hemodiafiltration. The in vivo study was carried out on 12 ESRD patients on regular hemodialysis treatment. The protocol was reviewed and approved by the local ethical committee. The in vivo clearances (K) at 300 ml/min of blood flow are reported in the following Table: [Table in text]. Beta-2-m reduction ratio exceeded 50% in all sessions. Beta-2-m mass balance executed by collection of spent dialysate and elution from the used filters evidenced that removal is obtained mostly by filtration while absorption is negligible. Excellent tolerance and hemocompatibility was observed in all the studied sessions.

Adsorption↗
PubMed1999

CRRT efficiency and efficacy in relation to solute size.

Removal of blood solutes in patients with decreased or absent glomerular filtration is the prime objective of continuous renal replacement therapies (CRRTs). However, because these blood solutes are of different molecular weights, factors such as the porosity and hydrophobicity of the filter membranes and the extracorporeal flow rates determine the CRRT that is the most effective filtration system. This article discusses both small and large solute removal, the interaction of convection and diffusion, and the potential for CRRTs to remove particular inflammatory mediators of acute renal failure.

Hemofiltration↗